Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Zentek's half-year profit comes from accounting gain, not sales, as C$18M raise lifts cash

A C$19.7M non-cash write-back turned Zentek's six months to September into a C$15.2M profit, while revenue stayed negligible and spending climbed.

17 Nov 2026 · Zentek Ltd. ZTEKF · Company news

Zentek Ltd. has swung to a C$15.2M net profit for the six months ended 30 September 2026, but the figure owes nothing to commercial traction. The Canadian company's board approved its unaudited interim statements on 16 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Zentek Ltd. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →